The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA
A
receptor and negatively modulating the α5 subtype of GABA
A
, and use of the compound of formula I for the treatment of GABA
A
receptor associated disorders. The general structure of formula I is shown below:
The invention further provides a method of modulation of one or more GABA
A
subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).
The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and negatively modulating the α5 subtype of GABAA, and use of the compound of formula I for the treatment of GABAA receptor associated disorders. The general structure of formula I is shown below:
The invention further provides a method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).
[EN] THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLONAPHTYRIDINE THÉRAPEUTIQUES
申请人:HELICON THERAPEUTICS INC
公开号:WO2008154447A1
公开(公告)日:2008-12-18
[EN] The invention provides a novel chemical series of formula (I), as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and negatively modulating the a5 subtype of GABAA, and use of the compound of formula (I) in the manufacture of a medicament for the treatment of GABAA receptor associated disorders. The invention further provides a method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I). [FR] L'invention concerne une nouvelle série chimique représentée par la formule (I), ainsi que des procédés d'utilisation de celle-ci pour une liaison avec le site de benzodiazépine du récepteur GABAA et pour une modulation négative du sous type a5 du GABAA, et l'utilisation du composé représenté par la formule (I) dans la fabrication d'un médicament destiné au traitement des troubles associés au récepteur GABAA. Cette invention concerne aussi un procédé de modulation d'un ou de plusieurs sous types de GABAA chez un animal qui consiste à administrer à cet animal une quantité efficace d'un composé représenté par la formule (I).